《通络药物系统干预心血管事件链专家共识》发布

Core Viewpoint - The release of the first expert consensus on the cardiovascular event chain provides a Chinese characteristic clinical drug treatment plan that integrates traditional Chinese medicine and Western medicine, aiming to systematically intervene in cardiovascular diseases [1][2][3] Group 1: Expert Consensus Overview - The expert consensus titled "Expert Consensus on Systematic Intervention of Cardiovascular Event Chain with Tongluo Drugs" was published during the 12th Chinese Association of Integrative Medicine Vascular Disease Conference [1] - The consensus addresses the need for new intervention methods for the cardiovascular event chain, which is characterized by a series of events leading to severe outcomes such as myocardial infarction and heart failure [1] Group 2: Mechanisms and Clinical Evidence - The consensus includes a series of Tongluo drugs (e.g., Jinlida granules, Tongxinluo capsules) and their mechanisms and clinical evidence for intervening in diseases related to the cardiovascular event chain, such as diabetes, stroke, coronary heart disease, arrhythmia, and heart failure [2] - Significant clinical evidence from national key research projects supports the breakthroughs in traditional Chinese medicine, including the prevention of type 2 diabetes and improvements in coronary plaque stability [2] Group 3: Impact and Future Prospects - The consensus is expected to enhance the prevention and treatment of cardiovascular diseases, significantly reducing their incidence and mortality rates [3] - The release of the consensus is anticipated to attract global attention to traditional Chinese medicine and stimulate further research in the integration of traditional and modern medical practices [3]